(MedPage Today) — SAN FRANCISCO — The addition of radionuclide therapy with 177Lu-PSMA-617 (Pluvicto) to enzalutamide (Xtandi) improved overall survival (OS) in patients with metastatic castration-resistant prostate cancer (CRPC), according…
Source link : https://www.medpagetoday.com/meetingcoverage/mgucs/114233
Author :
Publish date : 2025-02-14 19:59:50
Copyright for syndicated content belongs to the linked Source.
